Not available
Quote | Akari Therapeutics Plc (NASDAQ:AKTX)
Last: | $3.53 |
---|---|
Change Percent: | 0.55% |
Open: | $3.62 |
Close: | $3.53 |
High: | $3.87 |
Low: | $3.53 |
Volume: | 3,092 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
News | Akari Therapeutics Plc (NASDAQ:AKTX)
2024-06-05 08:53:22 ET More on Akari Therapeutics Akari gains despite leadership change amid portfolio shakeup Financial information for Akari Therapeutics Read the full article on Seeking Alpha For further details see: Akari Therapeutics announces interm...
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotec...
Message Board Posts | Akari Therapeutics Plc (NASDAQ:AKTX)
Subject | By | Source | When |
---|---|---|---|
What do you make of this? | Rogerthat1 | investorshub | 07/03/2023 10:19:08 PM |
$AKTX Good read | mick | investorshub | 07/03/2023 6:42:07 PM |
$AKTX The gaining | mick | investorshub | 07/03/2023 5:19:37 PM |
The now up | mick | investorshub | 07/02/2023 1:19:36 PM |
The gaining up | mick | investorshub | 07/01/2023 11:35:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
Akari Therapeutics Plc Website:
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotec...
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is ...
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan fo...